Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Cboe Europe - 06/21 05:27:53 pm
215.3 CHF   -0.53%
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19ROCHE : University of Missouri School of Medicine, Roche collaborate..
PR
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Latest news on ROCHE HOLDING LTD.
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19ROCHE : University of Missouri School of Medicine, Roche collaborate on first US..
PR
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
06/19Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
RE
06/19Roche, Foundation Medicine Reach Definitive Merger Agreement -- Update
DJ
06/19Roche, Foundation Medicine Reach Definitive Merger Agreement
DJ
06/15Roche's Gazyva Cancer Drug Outperforms MabThera
DJ
06/14Roche to Present Ocrevus Data Showing Delayed Wheelchair Need in MS Patients
DJ
06/14GENENTECH : Announces New OCREVUS (Ocrelizumab) Data on Long-Term Disability Ben..
BU
06/13ROCHE : CORRECTING and REPLACING FDA Approves Genentech’s Avastin (Bevaciz..
BU
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/11Takeda shareholder group aims to block $62 billion Shire deal
RE
06/11Takeda shareholder group aims to block $62 billion Shire deal
RE
06/11Roche's Venclexta Plus Rituxan Gets FDA Approval as Leukemia Treatment
DJ
06/08GENENTECH : Announces FDA Approval for Venclexta Plus Rituxan for People with Pr..
BU
06/07ROCHE : FDA Approves Genentech’s Rituxan (rituximab) For Pemphigus Vulgari..
BU
06/06IP Group Investee Microbiotica Enters Potential $534 Million Deal with Roche
DJ
06/05Roche's Hemlibra Gets FDA Priority Review
DJ
06/05ROCHE : FDA Grants Priority Review to Genentech’s HEMLIBRA (emicizumab-kxw..
BU
06/02ROCHE : Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizu..
BU
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
05/29ROCHE : Phase III IMpower130 Study Showed Genentech’s TECENTRIQ (Atezolizu..
BU
05/25AstraZeneca cancer drug hits second goal by extending survival
RE
05/21Roche Presents Positive Results From Hemlibra Trials
DJ
05/21GENENTECH : ’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Per..
BU
05/18AstraZeneca insists future is bright after big Crestor sales hit
RE
05/16Reducing Use of Roche Drug for Breast Cancer Didn't Hurt Efficacy, Study Says
DJ
05/16ROCHE : Phase III IMpower150 Study Showed Genentech’s TECENTRIQ and Avasti..
BU
05/16ROCHE : Follow-up Phase III Data Showed Genentech’s Alecensa Helped People..
BU
05/15Roche's Actemra Gets FDA Nod for Pediatric Subcutaneous Use
DJ
05/14ROCHE : FDA Approves Subcutaneous Formulation of Actemra for Use in Active Polya..
BU
05/14GENENTECH : to Present New Phase III Data for HEMLIBRA (emicizumab-kxwh) in Peop..
BU
05/10Roche's Phase 3 IMblaze370 Study Misses Primary Endpoint
DJ
05/10GENENTECH : Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) and C..
BU
05/08GENENTECH : to Present New Data from its Industry-Leading Oncology Portfolio at ..
BU
05/07Roche's Tecentriq Gets FDA Priority Review in First-Line Lung Cancer Treatmen..
DJ
05/07ROCHE : FDA Grants Priority Review to Genentech’s Cancer Immunotherapy TEC..
BU
05/02Fresenius Medical Care Appoints New EMEA Management Board Member
DJ
04/27Sanofi sees new acquisitions and drugs reviving growth
RE
04/26Overshadowed by Takeda bid, Shire reports solid start to year
RE
04/26Biosimilar worries takes shine off Roche's guidance hike
RE
04/26Roche Lifts Outlook as 1Q Sales Rise Above Expectations -- Update
DJ
04/26Correction to Roche Article on 1Q Sales
DJ
04/26Roche Raises Outlook After 1Q Sales Increase
DJ
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/23ROCHE : New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions..
BU
04/18GSK flags pharma M&A ambitions by poaching Roche deal-maker
RE
04/18Shire faces criticism on CEO pay policy as crunch week looms
RE
04/17ROCHE : FDA Grants Breakthrough Therapy Designation for Genentech’s HEMLIB..
BU
04/16GENENTECH : to Present New Data at AAN Highlighting Extensive Research for OCREV..
BU
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/09Novartis bets big on gene therapy with $8.7 billion AveXis deal
RE
04/03Roche's Alecensa Approved in Switzerland
DJ
03/28ROCHE : Tokyo court rejects Shire claim against Roche haemophilia drug
RE
03/26Singapore pharma on recovery path after worst output in decades
RE
03/26Roche's Tecentriq Improves Lung Cancer Treatment Results With Avastin
DJ
03/26ROCHE : Phase III IMpower150 Study Showed Genentech’s TECENTRIQ (Atezolizu..
BU
03/22Roche's Lucentis 0.3 Mg Prefilled Syringe Receives FDA Approval
DJ
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
RE
03/21ROCHE : FDA Approves Genentech’s Lucentis (ranibizumab injection) 0.3 mg P..
BU
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/21GlaxoSmithKline prescribes commercial reboot for pharma division
RE
03/20Roche says Tecentriq, chemo cut risk of death in type of lung cancer
RE
03/20ROCHE : Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizu..
BU
03/19GLOBAL ARTIFICIAL INTELLIGENCE AND A : Global Artificial Intelligence And Advanc..
AQ
03/19PTC THERAPEUTICS : FIREFISH Transitions into Pivotal Phase
AQ
03/19FOUNDATION MEDICINE : CMS issues final coverage decision for NGS cancer tests
AQ
03/17ROCHE : Federal Contracts Awarded to Companies in Indiana (March 17)
AQ
03/17ROCHE : Federal Contracts Awarded by Federal Agencies in North Dakota (March 17)
AQ
03/16KNOW ABOUT CERVICAL CANCER MARKET IN : New Research: Cervical Cancer Market &nda..
AQ
03/16ROCHE : Q-- 6 month Bridge ROCHE - DES MOINES
AQ
03/16ROCHE : Q-- 6 month Bridge ROCHE - IOWA CITY
AQ
03/16ROCHE : $1.31 Million Federal Contract Awarded to Roche Diagnostics
AQ
1  2  3  4  5  6  7  8  9  10Next
Financials ( CHF)
Sales 2018 55 696 M
EBIT 2018 18 523 M
Net income 2018 12 023 M
Debt 2018 4 036 M
Yield 2018 4,00%
P/E ratio 2018 15,01
P/E ratio 2019 14,44
EV / Sales 2018 3,36x
EV / Sales 2019 3,18x
Capitalization 183 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 256  CHF
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-12.19%183 625
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
MERCK AND COMPANY8.90%164 189
AMGEN7.07%123 203